Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01709032 · ClinicalTrials.gov registry record · Phase 1
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
A Phase 1 study, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01709032 is a Phase 1 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 9 participants.
The verdict
NCT01709032, a Phase 1 study, has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.
Interventions
- DRUG Deferasirox and deferiprone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-09 |
| Est. Completion | 2017-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01709032
The ClinicalTrials.gov registry entry for NCT01709032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deferasirox and deferiprone is the first listed.
NCT01709032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01709032 about?
NCT01709032 is a clinical study titled "Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia". We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.
What is the current status of trial NCT01709032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-09. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT01709032?
The interventions under investigation include: Deferasirox and deferiprone (DRUG).
Who is sponsoring clinical trial NCT01709032?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.